JP2016513687A - 置換キサンチンおよびその使用方法 - Google Patents

置換キサンチンおよびその使用方法 Download PDF

Info

Publication number
JP2016513687A
JP2016513687A JP2016502354A JP2016502354A JP2016513687A JP 2016513687 A JP2016513687 A JP 2016513687A JP 2016502354 A JP2016502354 A JP 2016502354A JP 2016502354 A JP2016502354 A JP 2016502354A JP 2016513687 A JP2016513687 A JP 2016513687A
Authority
JP
Japan
Prior art keywords
dimethyl
lcms
purine
dione
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016502354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513687A5 (enExample
Inventor
バートランド・チェナード
スペンサー・デイビッド・キンボール
ランドール・ガラシュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hydra Biosciences LLC
Original Assignee
Hydra Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hydra Biosciences LLC filed Critical Hydra Biosciences LLC
Publication of JP2016513687A publication Critical patent/JP2016513687A/ja
Publication of JP2016513687A5 publication Critical patent/JP2016513687A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016502354A 2013-03-14 2014-03-14 置換キサンチンおよびその使用方法 Withdrawn JP2016513687A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784448P 2013-03-14 2013-03-14
US61/784,448 2013-03-14
PCT/US2014/027166 WO2014152287A2 (en) 2013-03-14 2014-03-14 Substituted xanthines and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2016513687A true JP2016513687A (ja) 2016-05-16
JP2016513687A5 JP2016513687A5 (enExample) 2017-07-13

Family

ID=50819943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502354A Withdrawn JP2016513687A (ja) 2013-03-14 2014-03-14 置換キサンチンおよびその使用方法

Country Status (7)

Country Link
US (2) US20140275528A1 (enExample)
EP (1) EP2970316B1 (enExample)
JP (1) JP2016513687A (enExample)
AR (1) AR095561A1 (enExample)
TW (1) TW201444844A (enExample)
UY (1) UY35424A (enExample)
WO (1) WO2014152287A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022525506A (ja) * 2019-03-20 2022-05-17 ゴールドフィンチ バイオ，インク． ピリダジノン及びその使用法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023831A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
WO2016086008A1 (en) * 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule aldehyde dehydrogenase inhibitors and methods of use thereof
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
WO2018157800A1 (en) * 2017-02-28 2018-09-07 National Institute Of Biological Sciences, Beijing Mlkl inhibitors
GB201712110D0 (en) * 2017-07-27 2017-09-13 Thomas Helledays Stiftelse För Medicinsk Forskning New compounds and uses
CA3075727A1 (en) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
US11623930B2 (en) 2018-03-05 2023-04-11 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
CN113603690B (zh) * 2021-08-02 2022-10-25 南开大学 一种含黄嘌呤-8-基的(e)-丙烯酸衍生物及其制备方法和应用
CN115636831B (zh) * 2022-10-27 2024-11-08 中国药科大学 稠合嘧啶二酮类化合物、其用途以及药物组合物
CN116023336A (zh) * 2022-12-13 2023-04-28 河北医科大学 一种具有Nav1.7钠离子通道靶向抑制作用的化合物及其药物组合物和用途
CN116217575B (zh) * 2023-01-09 2025-01-10 广东赛烽医药科技有限公司 一种8-溴茶碱的制备方法
CN118459461A (zh) * 2023-02-08 2024-08-09 中国科学院上海药物研究所 黄嘌呤类化合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090018148A1 (en) * 2005-12-07 2009-01-15 Ucb Pharma, S.A. Xanthine Derivatives, Processes For Preparing Them And Their Uses
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022525506A (ja) * 2019-03-20 2022-05-17 ゴールドフィンチ バイオ，インク． ピリダジノン及びその使用法
JP7571039B2 (ja) 2019-03-20 2024-10-22 ゴールドフィンチ バイオ，インク． ピリダジノン及びその使用法

Also Published As

Publication number Publication date
US20140275528A1 (en) 2014-09-18
AR095561A1 (es) 2015-10-28
WO2014152287A2 (en) 2014-09-25
EP2970316B1 (en) 2017-11-08
WO2014152287A4 (en) 2015-02-19
EP2970316A2 (en) 2016-01-20
WO2014152287A9 (en) 2015-04-23
WO2014152287A3 (en) 2014-12-04
UY35424A (es) 2014-10-31
TW201444844A (zh) 2014-12-01
US20160145257A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
US11958854B2 (en) Substituted xanthines and methods of use thereof
JP2016513687A (ja) 置換キサンチンおよびその使用方法
JP6573968B2 (ja) ＴＲＰＣ５調節因子としての、精神神経障害の処置のためのチエノおよびフロ［２，３−ｄ］ピリミジン−２，４［１Ｈ，３Ｈ］−ジオン誘導体
EP3180342B1 (en) Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
JP6667091B2 (ja) Ｔｒｐｃ５調節因子としての、精神神経障害の処置のためのキナゾリン−２，４（１ｈ，３ｈ）−ジオン誘導体
HK1240215B (zh) 取代的黄嘌呤及其使用方法
HK1240215A1 (en) Substituted xanthines and methods of use thereof
JP2017523228A (ja) ピリド［３，４−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
HK1217329B (en) Substituted xanthines and methods of use thereof
BR112015021164B1 (pt) Composto de xantina substituída e seu sal

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20151029

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170530

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20171127